Dosing Starts in Athira’s Phase 2 ACT-AD Trial Testing ATH-1017; Enrollment Ongoing

Dosing Starts in Athira’s Phase 2 ACT-AD Trial Testing ATH-1017; Enrollment Ongoing
Athira Pharma has begun dosing patients in its Phase 2 clinical trial evaluating ATH-1017, an investigational small molecule for the treatment of mild to moderate Alzheimer’s disease. Clinical efficacy will be demonstrated by improvements in cognition and functional assessments among participants, compared with a placebo. “The initiation of our second late-stage study for ATH-1017 represents a significant milestone for Athira as we advance our clinical program to treat this area of immense medical need,” Hans Moebius, MD, PhD, chief medical officer at Athira, said in a press release. Called ACT-AD, the randomized, double-blind trial (NCT04491006) will evaluate the safety and efficiency of ATH-1017 (previously known as NDX-1017), compared with a placebo, in the treatment of mild to moderate Alzheimer’s. The trial expects to recruit a total of 75 participants, ages 55 to 85, at several clinical sites across the U.S. and Australia. More information and contacts can be found here. Similar to the company’s LIFT-AD Phase 2/3 trial, participants will be randomly assigned to receive either a low or high dose of ATH-1017 or a placebo, delivered subcutaneously (under the skin) daily for 26 weeks. Neither participants nor researchers will know which patient is given the medication and which the placebo. The study will measure quantitative electroencephalography (qEEG), as a biomarker for brain function, and event-related potential (ERP) to assess working memory processing speed and executive function. “The use of qEEG and ERP 300 as physiological outcome measures and indicators of improved function in brain networks could be highly valuable to the field as a whole,” said Charles Bernick, MD, co-investigator at University of Washington Alzheimer
Subscribe or to access all post and page content.